Abstract
Materials and methods
The medical records of 23 patients with pure ovarian dysgerminoma treated by conservative surgery at SSK Ankara Maternity Hospital between 1991 and 2001 were reviewed retrospectively. Pregnancy outcomes and menstrual function after conservative surgery were analyzed.
Results
Seven patients (30%) were incompletely staged and were assumed to be stage IA due to intraoperative findings. Fifteen patients (70%) were surgically staged. As a result 15 patients (65.2%) were diagnosed to be stage I while 2 patients (8.6%) were staged II and 6 patients (26%) were staged III. Wedge biopsy of contralateral ovary was performed in 17 patients (74%) and tumor was diagnosed in 2 (11.7%). Adjuvant chemotherapy was applied in 16 (70%) of the cases. BEP (bleomycin, etoposide, and cisplatin) was the most frequently used regimen (39%). Recurrences were seen in 3 (13%) patients. The sites of recurrences were contralateral ovary in all cases. Recurrences were treated with surgery and radiotherapy. None of the patients died of disease. Nine patients were sexually active. Five of these patients had prior live births. Three of the primiparous patients delivered after treatment. Five pregnancies occurred in 3 nulliparous patients at the time of primary surgery. Three of these reached term and healthy babies were delivered. One pregnancy was terminated at 18 weeks of gestation due to anencephaly and a dilatation and curettage was performed at 6th week in another patient. Menstrual problems occurred in 4 (17.3%) of the 23 patients.
Conclusion
Fertility sparing treatments are safe in patients with pure ovarian dysgerminoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bakri YN, Ezzat A, Akhtar, Dohami, Zahrani (2000) Malignant germ cell tumors of the ovary: pregnancy considerations. Eur J Obstet Gynecol 90:87–91
Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT (1999) Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 17:2670–2675
Bridgewater JA, Rustin GJS (1999) Management of non-epithelial ovarian tumors. Oncology 57:89–98
Casey AC, Bhodauria S, Shapter A, Nieberg R, Berek JS, Farias-Eisner R (1996) Dysgerminoma: the role of conservative surgery. Gynecol Oncol 63:352–357
Culine S, Lhomme C, Kattan J, Duvillard P, Michel G, Gerbaulet A, Droz J-P (1995) Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen year experience at the Institute Gustave Roussy. Gynecol Oncol 58:344–348
Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJS (1997) Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15:620–624
Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G et al (1998) Favorable outcome of ovarian malignancies treated with cisplatin or carboplatin based chemotherapy: a Hellenic Cooperative Oncology Group Study. Gynecol Oncol 70:70–74
Ezzat A, Raja M, Bakri Y, Subhi J, Schwartz P et al (1999) Malignant ovarian germ cell tumors: a survival and prognostic analysis. Acta Oncol 38:455–460
FIGO Cancer Committee (1986) Staging announcement. Gynecol Oncol 25:383
Gershenson DM (1988) Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 6:270–275
Gershenson DM, Wharton T, Kline RC, Larson DM, Kavanagh JJ, Rutledge FN (1986) Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma: potential for cure and preservation of reproduction capacity. Cancer 58:2594–2599
Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL et al (1990) Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide and cisplatin. J Clin Oncol 8:715–720
Jacobs AJ, Harris M, Deppe G, DasGupta I, Cohen CJ (1982) Treatment of recurrent and persistent germ cell tumors with cisplatin, vinblastine and bleomycin. Obstet Gynecol 59:129–132
Kurman RJ, Norris HJ (1977) Malignant germ cell tumors of the ovary. Hum Pathol 8:551–564
Mitchell MF, Gershenson DM, Soeters RP, Eifel PJ, Delclos L, Wharton JT (1991) The long term effects of radiotherapy on patients with ovarian dysgerminoma. Cancer 67:1084–1090
Schwartz PE (1984) Combination chemotherapy in the management of ovarian germ cell malignancies. Obstet Gynecol 64:564–572
Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA (1985) Vincristine, dactinomycine and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a Gynecologic Oncology Group Study. Cancer 56:243–248
Stanton G, Bosl G, Whitmore WC (1985) VAB-6 as initial treatment of patients with advanced seminoma. J Clin Oncol 3:336–339
Tewari K (2000) Malignant germ cell tumors of the ovary. Obstet Gynecol 95:128–133
Thomas GM, Dembo A, Hacker NF, DePetrillo AD (1987) Current therapy for dysgerminoma of the ovary. Obstet Gynecol 70:268–275
Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L (1989) Cisplatin, vinblastine and bleomycin in advanced and recurrent ovarian germ cell tumors. Ann Intern Med 111:22–27
Williams SD, Blessing JA, Hatch KD, Homesley HD (1991) Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 9:1950–1955
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boran, N., Tulunay, G., Caliskan, E. et al. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet 271, 104–108 (2005). https://doi.org/10.1007/s00404-004-0601-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-004-0601-6